GSK/MMV win FDA 'breakthrough' status for malaria drug tafenoquine

The US FDA has granted breakthrough therapy designation to GlaxoSmithKline's (GSK) and Medicines for Malaria Venture's (MMV) experimental drug tafenoquine as to treat and prevent relapse of Plasmodium vivax malaria, a neglected tropical disease, which is a major cause of uncomplicated malaria.